01.30.12
Ira Baeringer has been appointed vice president of business development at Intellipharmaceutics International Inc. Mr. Baeringer will assist the commercialization of products in the company’s controlled-release generic drug Abbreviated New Drug Applications (ANDA) portfolio and 505(b)(2) New Drug Application (NDA) portfolio across markets both in and outside the U.S.
Mr. Baeringer has 20 years of experience in pharmaceutical licensing, development, supply, acquisitions, divestitures, and alliance management. Most recently he was with sanofi-aventis from 2009 to 2012, and was previously with Sandoz Inc., Dorland Sweeney Jones, Forest Pharmaceuticals, Inc. and TEVA Pharmaceuticals USA.
"We are pleased to have Ira join the Intellipharmaceutics team as we build our leadership group and infrastructure to help position us for growth and expansion of our core business," said Dr. Isa Odidi, chief executive officer. "His experience will be of great value as Intellipharmaceutics continues to pursue implementation of its commercialization plans in the U.S. market through the exploration of new drug product opportunities and new strategic partnerships."
Mr. Baeringer has 20 years of experience in pharmaceutical licensing, development, supply, acquisitions, divestitures, and alliance management. Most recently he was with sanofi-aventis from 2009 to 2012, and was previously with Sandoz Inc., Dorland Sweeney Jones, Forest Pharmaceuticals, Inc. and TEVA Pharmaceuticals USA.
"We are pleased to have Ira join the Intellipharmaceutics team as we build our leadership group and infrastructure to help position us for growth and expansion of our core business," said Dr. Isa Odidi, chief executive officer. "His experience will be of great value as Intellipharmaceutics continues to pursue implementation of its commercialization plans in the U.S. market through the exploration of new drug product opportunities and new strategic partnerships."